AGTC appoints Jim Robinson to its Board of Directors

– USA, FL –  Applied Genetic Technologies Corporation (Nasdaq: AGTC) today announced the appointment of President and CEO of Urovant Sciences, Jim Robinson to its Board of Directors.

“We are honored to have Jim join our Board of Directors, where his exemplary track record of execution as an executive at leading biotech and pharma companies will be invaluable to AGTC as we seek to deliver on the clinical and commercial promise of our robust pipeline including our late stage XLRP and ACHM programs,” said CEO, Sue Washer.

About James Robinson

Mr. Robinson is an expert in building, deploying, and leading successful organizations from their earliest stages of development through their emergence as commercial enterprises, and has successfully led multiple global businesses, operations, and commercial ventures over the past 28 years. A proven industry leader, Mr. Robinson served as a member of the Urovant Board of Directors before being appointed Urovant’s CEO in 2020. Before his role at Urovant, Mr. Robinson held the position of President and COO at Paragon Biosciences. He came to this role after serving as the President and COO of Alkermes, where he was responsible for global commercial operations, new product planning, corporate planning, manufacturing, quality, human resources, and business development.

“I am excited to join AGTC’s Board of Directors at a time when the organization has already made impressive progress developing its pipeline of gene therapies, particularly in ophthalmology,” said Mr. Robinson. “I look forward to contributing my operational and commercial experience and working closely with Sue and the executive leadership team.”

Before Alkermes, Mr. Robinson spent more than a decade at Astellas U.S. – most recently as President, Americas Operations and previously as President of Astellas Pharma US, where he was responsible for leading the U.S. commercial organization. Before Astellas, Mr. Robinson spent thirteen years at Schering-Plough Pharmaceuticals where his last role was VP, Hepatitis Sales and Managed Care.

Mr. Robinson serves on the Board of Directors for Urovant Sciences and is an advisor to BridgeBio Pharma. Mr. Robinson previously served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America and served as Chairman of PhRMA’s State Committee. He is a founding member of MATTER, the Commercial Club of Chicago, and a member of the Chicago Chapter of the Young Presidents Organization. Mr. Robinson received a Bachelor of Science degree from DePaul University.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia. Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address the substantial unmet clinical need in optogenetics, ontology, and CNS disorders, including entering into strategic collaborations with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

For more information: https://agtc.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team